Inspire Medical Systems (INSP) Q3 2026 earnings review
Inspire wins a 2028 billing code, but 2026 sales shrink
Inspire Medical Systems, the maker of implanted sleep-apnea nerve stimulators, grew sales from last quarter while year-over-year revenue kept falling. Third-quarter revenue dropped 8% from a year ago to $207 million, which beat the company's own plan as U.S. doctors adjusted to new Medicare billing rules. Chief executive Tim Herbert kept the middle of the full-year sales outlook unchanged, so by our math the plan points to a 10% drop in the fourth quarter.
| Revenue | $206.7M -7.9% from a year ago, +3.0% from last quarter |
|---|---|
| Operating margin, excluding one-offs | 0.9% 4.9% a year ago |
| Full-year revenue outlook | Narrowed $850–860M (middle of the range unchanged at -6%) |
| Initial 2027 revenue outlook | Low-single digit growth first issued in presentation |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because a long-term billing win was offset by a weak 2027 growth preview. Medical regulators approved a dedicated billing code for the newer Inspire V implant starting in 2028, which removes a major long-term hurdle, and a Q3 beat shows the prior plan was cautious. The bad news: management previewed only low-single-digit sales growth for 2027 against an easy 2026 comparison, while restructuring and legal settlements pushed the third quarter into a $24 million reported loss.
The question now is whether the 2026 sales drop is just temporary billing friction or permanent demand loss from weight-loss drugs and new rivals. If billing friction is the only problem, higher proposed 2027 Medicare hospital payments will lift implant volumes quickly; if weight-loss drugs are shrinking the patient pool, growth will stay in the low single digits. Management's formal 2027 revenue plan next quarter will settle it.
🐂 Bull Case
A Dedicated Billing Code Arrives for 2028
Inspire Medical Systems makes implanted nerve stimulators that keep airways open during sleep. Its fifth-generation device, Inspire V, uses a single wire lead, and the lack of a dedicated medical billing code (CPT code) has disrupted U.S. sales all year. After rejecting an initial request in May, the American Medical Association panel approved a dedicated Category I billing code in September.
"When this takes effect in January 2028, a dedicated code set will give physicians and hospitals enhanced clarity around coding and reimbursement," chief executive Tim Herbert said. The approval removes the risk that doctors must bill under temporary modifiers forever. However, the new code does not start for five quarters, and a medical committee still has to set the doctor payment rate in mid-2027.
What to watch: the final 2027 Medicare hospital and surgery-center payment rules due in November 2026. If Medicare locks in its proposed 12% to 15% facility rate increases, clinics will have a financial reason to schedule more implants before the 2028 code starts.
Sequential Growth Returns as Billing Friction Eases
In the first half of 2026, U.S. hospitals and surgeons slowed implants because Medicare discontinued the old billing code for Inspire V. Management rolled out temporary hospital billing codes (C-codes) in April and educated clinics on how to submit claims. In the third quarter, revenue rose 3.0% from the second quarter to $206.7 million, beating the company's plan for an 8% to 10% year-over-year drop.
Herbert said "there is greater comfort among implanting physicians with the current coding dynamic." Only two regional Medicare contractors cut surgeon fees under the temporary billing modifier, and all six states in Medicare's prior-approval pilot (WISeR) adopted the new hospital code. Meanwhile, the shift to Inspire V lifted gross margin by 0.2 percentage points from a year ago to 86.0%, and new conference studies backed the therapy's health benefits.
What to watch: whether sequential revenue growth continues in the first quarter of 2027 after the holiday season. A drop worse than normal first-quarter seasonality would show that doctor comfort alone cannot overcome the lower surgeon fee.
🐻 Bear Case
The Outlook Leaves Fourth-Quarter Sales Down 10%
Herbert highlighted that third-quarter U.S. performance beat internal expectations as doctors grew comfortable with billing rules. Yet the sleep-therapy maker only narrowed its full-year revenue forecast to $850 million to $860 million, leaving the $855 million middle of the range unchanged. Because third-quarter revenue beat the prior plan by $2.4 million, holding the full-year midpoint trims the fourth-quarter outlook by the same amount.
- Third-quarter revenue: $206.7 million, down 7.9% from a year ago
- Fourth-quarter revenue implied by the full-year outlook: $243.1 million at the middle of the range, down 9.6% from a year ago by our math
- Initial 2027 revenue preview: "Anticipating low-single digit growth in 2027" on slide 26 of the investor presentation
A deeper year-over-year decline in the fourth quarter cuts against the claim that billing friction is steadily fading. Furthermore, the first half of 2026 suffered from severe billing disruption, so a low-single-digit rebound in 2027 barely recovers the lost ground.
What to watch: formal 2027 revenue outlook on the fourth-quarter report in early 2027. A forecast below 5% growth against an easy 2026 comparison would indicate that demand is slowing beyond temporary billing issues.
Operating Profit Now Rests on the Fourth Quarter
Falling sales are squeezing profitability even before one-time charges. Reported selling and administrative costs (marketing, sales reps, and overhead) jumped 18.4 percentage points of revenue from a year ago to 89.2% because of restructuring and legal bills. Excluding those one-offs, by our math, selling and administrative costs still rose 4.2 percentage points to 74.4% of revenue, while research and development stayed flat at 10.7%.
As a result, operating margin excluding one-offs fell 4.0 percentage points from a year ago to 0.9%, or $1.9 million. For the first nine months of 2026, operating profit excluding one-offs totals $5.4 million. Yet management kept its full-year operating margin target at 4.5% to 5.5% excluding one-offs. By our math, that leaves $37.4 million of profit—a 15.4% margin—for the fourth quarter alone.
What to watch: fourth-quarter operating margin excluding one-offs against the implied 15.4% target. A shortfall in high-deductible fourth-quarter procedures would cause Inspire to miss its full-year profit plan.
Legal Costs Mount While Inventory Keeps Piling Up
Inspire faces a Department of Justice investigation into its marketing and billing practices, patent lawsuits with rival Nyxoah, and shareholder lawsuits. This quarter, the device maker also booked a $7.0 million charge for the "proposed settlement of a pixel-tracking class action" alongside $3.6 million in ongoing legal fees. Meanwhile, net inventory on the balance sheet climbed again even though sales shrank.
- Third-quarter legal fees and settlement: $10.6 million combined, or 5.1% of revenue by our math
- Net inventories: $179.0 million, up 26.2% from a year ago and up 5.0% from last quarter by our math
- Inventory relative to sales: 86.6% of third-quarter revenue, up from 63.2% a year ago by our math
Holding $179.0 million of inventory—more than six quarters of manufacturing cost—ties up cash and creates write-down risk as clinics stop using older Inspire IV units.
What to watch: inventory reserves and legal disclosures in the third-quarter 10-Q filing. Any write-down of older Inspire IV stock or new settlement reserves would show these balance-sheet risks turning into losses.
Risks this quarter didn't answer
Three standing threats to patient demand received no new figures in the third-quarter release or presentation.
- Weight-loss drugs (GLP-1s): previously flagged as a near-term sales headwind; the quarterly filing's risk discussion will show if patient deferrals worsened.
- Medicare prior-approval pilot (WISeR): active in six states; CMS announcements will show if the agency expands the program to more states in 2027.
- Rival implants: Nyxoah launched its competing Genio sleep device in the U.S.; fourth-quarter center productivity will show if rivals are taking share.
👓 Other Themes
Project Horizon Restructuring Recognizes $24 Million Charge
In August, Inspire launched a cost-cutting program it calls Project Horizon, focused on "Optimizing organizational structure and supply chain to reallocate $30 million of annualized operating expense to drive future revenue growth." In the third quarter, the company recorded $24.1 million in pre-tax restructuring charges—about 95% of the expected $25 million total—and a $4.1 million stock-pay credit from employee departures. Management plans to redirect the savings into patient scheduling and education starting in 2027.
💲 Other KPIs
Cash generated from operations doubled from $23.2 million last quarter, lifting total cash and investments to $453.1 million. However, operating cash flow fell 32.3% from $68.5 million a year ago because net earnings dropped and last year's third quarter included a one-time catch-up in customer collections after a billing-portal delay.
Weighted average diluted shares fell 2.3% from 29.6 million a year ago and stayed flat from last quarter. The medical-device maker bought back $175 million of stock in 2025, which lowered the share count, but it has not repurchased shares in 2026 despite holding $453.1 million in cash and investments with zero debt.
Money owed by hospitals and clinics for delivered devices fell 3.0% from a year ago and rose 1.3% from last quarter, moving in line with third-quarter sales. Since December 2025, accounts receivable have dropped 12.5% from $119.7 million as billing-portal collection delays from 2025 cleared.
🔮 Guidance
Unchanged at the middle of the range. The sleep-therapy group tightened its forecast by $15 million on both ends, keeping the midpoint at $855 million, or a 6.2% drop from 2025. By our math, that leaves $243.1 million for the fourth quarter—a 9.6% drop from a year ago, steeper than the third quarter's 7.9% decline. After a $125 million cut in the first quarter and a $5 million raise in the second, the full-year target has stabilized.
Unchanged at the middle of the range. The plan still calls for a 5.0% operating margin excluding one-offs this year, down from 7.3% in 2025. Because the first nine months delivered a 0.9% margin, by our math, the fourth quarter must reach a 15.4% margin ($37.4 million in operating profit) on seasonally higher year-end procedure volume.
Raised. Management lifted the middle of the range by $0.05 to $1.30 per share, which still represents a 46.3% drop from $2.42 in 2025. With $0.38 earned in the first nine months, by our math, the outlook leaves $0.92 per share for the fourth quarter, helped by a lower share-count assumption of 28.9 million.
Cut. The middle of the range moved down by $0.105 to a loss of $0.23 per share, as the new $7.0 million legal settlement and $24.1 million in Project Horizon restructuring charges weighed on reported results. By our math, after a loss of $1.23 per share in the first nine months, the plan requires $1.00 of reported profit per share in the fourth quarter.
Raised on a reported basis. Inspire lifted its reported tax-rate assumption to 120%–175% because employee stock awards vested at lower values than when granted, creating $16.0 million in non-deductible tax charges over the first nine months. Excluding one-offs, the tax rate outlook narrowed to 33%–34%, slightly above the 32.7% rate recorded in the first nine months.
Equipment spending held; share count trimmed. Capital spending remains at $35 million to $40 million following two cuts earlier in the year. Management lowered its full-year diluted share estimate by 0.5 million to 28.9 million, matching the third quarter's actual share count and reflecting employee share forfeitures from the Project Horizon layoffs.
❓ Key Questions
Why does 2027 revenue grow only low-single digits?
The first half of 2026 lost about $60 million in sales to billing disruption. If doctors are now comfortable with the codes and Medicare proposes 12% to 15% higher hospital payments for 2027, why does slide 26 preview only low-single-digit growth next year?
What are the actual prior-authorization and U.S. implant volumes?
Management calls insurance prior-authorization submissions its main leading indicator, yet the release gives no numbers for submissions or U.S. procedures. Without those counts, investors cannot tell if patient demand is recovering or if weight-loss drugs are shrinking the funnel.
How much of the $179 million inventory is Inspire IV?
Net inventory has grown to $179.0 million—more than six quarters of cost of goods sold—even after Project Horizon wrote down $24.1 million in restructuring costs. How much older Inspire IV stock remains on the books, and could it require a write-down?
What is the status of the Justice Department investigation?
Inspire spent $3.6 million this quarter ($8.7 million year-to-date) on legal fees for the Department of Justice billing probe and Nyxoah patent suits, plus $7.0 million to settle a privacy suit. Has the government made any demands regarding billing practices?